Turning Point Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.119 million compared to USD 5.16 million a year ago. Net loss was USD 123.09 million compared to USD 56.27 million a year ago. Basic loss per share from continuing operations was USD 2.48 compared to USD 1.14 a year ago.
For the six months, sales was USD 0.548 million compared to USD 30.37 million a year ago. Net loss was USD 197.53 million compared to USD 91.78 million a year ago. Basic loss per share from continuing operations was USD 3.98 compared to USD 1.87 a year ago.